Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nilotinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Apotex Launches First Generic Tasigna® with 180 Days of U.S. Exclusivity
Details : Tasigna-Generic (Nilotinib HCl) is a kinase inhibitor indicated to treat certain types of leukemia, including newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia.
Product Name : Tasigna-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 27, 2025
Lead Product(s) : Nilotinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Recipient : Formosa Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Apotex Expands Clobetasol Deal with Formosa to Mexico for Ocular Pain Treatment
Details : Under the licensing agreement, Apotex will hold the commercialization rights of APP13007 (Clobetasol Propionate) in Mexico. It is being indicated for POI and pain associated with eye.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Undisclosed
May 06, 2025
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Recipient : Formosa Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Capsaicin
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : Grunenthal
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Apotex Licenses Exclusive Canadian Rights to Qutenza from Grünenthal
Details : Apotex will have the exclusive Canadian rights to Qutenza (capsaicin), a topical, non-systemic, non-opioid pain patch indicated for the management of neuropathic pain.
Product Name : Qutenza
Product Type : Plant Extract/Herbal
Upfront Cash : Undisclosed
February 24, 2025
Lead Product(s) : Capsaicin
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Grunenthal
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Modafinil
Therapeutic Area : Sleep
Study Phase : Approved FDF
Recipient : Teva Pharmaceutical Industries
Deal Size : Undisclosed
Deal Type : Acquisition
Apotex Acquires US rights to PROVIGIL® (modafinil) and NUVIGIL® (armodafinil)
Details : Acquiring the US rights to PROVIGIL (modafinil) and NUVIGIL (armodafinil) indicated to improve wakefulness in adult patients marks a strategic milestone for Apotex.
Product Name : Provigil
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 09, 2025
Lead Product(s) : Modafinil
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Recipient : Teva Pharmaceutical Industries
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Cetrorelix Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Apotex Corp. Launches Generic Fertility Treatment Injectable Cetrorelix® in the US
Details : Cetrorelix Acetate for Injection is a synthetic decapeptide with GnRH antagonist, indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.
Product Name : Cetrotide-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 14, 2024
Lead Product(s) : Cetrorelix Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Study Phase : Phase III
Recipient : Formosa Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Formosa Pharmaceuticals Announce Licensing Agreement with Apotex for Clobetasol Propionate
Details : Through the licensing agreement, Apotex will gain exclusive rights of APP13007 (clobetasol propionatei) in Canada for commercialization to treat inflammation and pain following ocular surgery.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Undisclosed
May 08, 2024
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Highest Development Status : Phase III
Recipient : Formosa Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Dasatinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Apotex Launches Generic Dasatinib Tablets in The U.S.
Details : Sprycel (dasatinib) is an oral film-coated tablet, a protein kinase inhibiting small molecule drug. It is indicated for the treatment of chronic myeloid leukemia.
Product Name : Sprycel-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 09, 2024
Lead Product(s) : Dasatinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tretinoin,Benzoyl Peroxide
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Recipient : SEARCHLIGHT PHARMA
Deal Size : Undisclosed
Deal Type : Acquisition
Apotex Acquires Searchlight, a Canadian Specialty Innovative Branded Pharma Company
Details : Apotex will commercialize Twyneo (tretinoin), a retinoic acid receptor agonist in combination with Benzoyl Peroxide indicated for the topical treatment of acne vulgaris.
Product Name : Twyneo
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 06, 2024
Lead Product(s) : Tretinoin,Benzoyl Peroxide
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Recipient : SEARCHLIGHT PHARMA
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Recipient : Harrow
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Harrow Licenses Canadian Rights to Apotex for Five Ophthalmic Products
Details : Through a licensing agreement, Apotex will market Verkazia (cyclosporine) ophthalmic emulsion, a calcineurin inhibitor indicated for treating vernal keratoconjunctivitis in children and adults.
Product Name : Vevye
Product Type : Peptide
Upfront Cash : Undisclosed
February 15, 2024
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Recipient : Harrow
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Tretinoin,Benzoyl Peroxide
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Recipient : SEARCHLIGHT PHARMA
Deal Size : Undisclosed
Deal Type : Acquisition
Apotex to Acquire Searchlight Pharma, a Canadian Specialty Branded Pharmaceutical Leader
Details : Through acquisition, Apotex will commercialize Twyneo (tretinoin), a retinoic acid receptor agonist combined with Benzoyl Peroxide for treating acne vulgaris in patients aged 9 and older.
Product Name : Twyneo
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 04, 2024
Lead Product(s) : Tretinoin,Benzoyl Peroxide
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Recipient : SEARCHLIGHT PHARMA
Deal Size : Undisclosed
Deal Type : Acquisition